Physician profile
David Kaiser
NPI 1083708564
$4,313.74
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $979 · 2020: $2,391 · 2021: $808 · 2022: $57.70 · 2023: $79.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,415.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $506.19 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $424.16 | 2019-2021 | |
| Abbvie INC. | $296.12 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $160.10 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $124.83 | 2019-2023 | Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $46.66 | 2019-2021 | |
| Alkermes, INC. | $43.76 | 2021-2022 | |
| Lundbeck LLC | $42.24 | 2019-2020 | |
| Adlon Therapeutics L.P. | $40.69 | 2019 | |
| Neos Therapeutics, Lp | $40.53 | 2019 | |
| Shire North American Group INC | $40.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.77 | 2021 | |
| Vanda Pharmaceuticals INC. | $24.46 | 2019 | |
| Ironshore Pharmaceuticals INC. | $21.63 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioxcel Therapeutics, INC. | $20.87 | 2023 | Igalmi |
| Jazz Pharmaceuticals INC. | $19.42 | 2021 | |
| Alfasigma USA, INC. | $17.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kaiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.